8-K: Surgery Partners Reports Strong Q4 and Full Year 2024 Results, Issues 2025 Guidance

Surgery Partners announces a 17.5% increase in Q4 revenue and provides 2025 revenue and Adjusted EBITDA guidance.

Summary

• Surgery Partners, Inc. reported its fourth quarter and full year 2024 financial results.
• Revenue for the fourth quarter increased by 17.5% to $864.4 million compared to $735.4 million in the same period of 2023.
• Same-facility revenues increased by 5.6% in the fourth quarter, driven by a 5.1% increase in same-facility cases and a 0.5% increase in revenue per case.
• The company reported a net loss attributable to Surgery Partners, Inc. of $108.5 million for the fourth quarter.
• Adjusted EBITDA for the fourth quarter increased by 15.1% to $163.8 million.
• Full year 2024 revenue increased by 13.5% to $3.1 billion compared to $2.7 billion in 2023.
• Same-facility revenues for the full year increased by 8.0%, with a 3.9% increase in same-facility cases and a 4.0% increase in revenue per case.
• The net loss attributable to Surgery Partners, Inc. for the full year was $168.1 million.
• Adjusted EBITDA for the full year increased by 16.0% to $508.2 million, with an Adjusted EBITDA margin of 16.3%.
• The company expects full year 2025 revenue to be in the range of $3.30 billion to $3.45 billion and Adjusted EBITDA to be in the range of $555 million to $565 million.
• Surgery Partners had a liquidity position of over $770 million as of the end of 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue and EBITDA growth, coupled with a healthy liquidity position. While there is a net loss, the adjusted figures and future guidance are encouraging.

Positives

• Strong revenue growth in both Q4 and full year 2024.
• Significant increase in Adjusted EBITDA and expansion of Adjusted EBITDA margin.
• Healthy liquidity position to fund future acquisitions and growth initiatives.
• Consistent and predictable organic growth with strong same-facility revenue growth.
• Deployment of capital on accretive acquisitions and de novo facilities.
• Strong cash flow from operating activities.
• The company is not expected to pay federal income taxes until 2029.

Negatives

• The company reported a net loss attributable to Surgery Partners, Inc. of $108.5 million for the fourth quarter.
• The company reported a net loss attributable to Surgery Partners, Inc. of $168.1 million for the full year.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include reductions in payments from government health care programs and private insurance payors, the ability to contract with private insurance payors, and changes in payor or surgical case mix.
• Other risks include failure to maintain relationships with physicians, the impact of payor controls, integration of acquired businesses, supply chain issues, competition, and the ability to attract and retain qualified healthcare professionals.
• The company also faces risks related to compliance with healthcare laws and regulations, legal and regulatory proceedings, cybersecurity attacks, economic conditions, indebtedness, and the impact of pandemics.

Future Outlook

The company projects full year 2025 revenue to be in the range of $3.30 billion to $3.45 billion and Adjusted EBITDA to be in the range of $555 million to $565 million.

Management Comments

• Eric Evans, Chief Executive Officer, stated, 'We are pleased to report another year of mid-teens growth, while continuing to expand margin.'
• Eric Evans also noted that the 2024 results are a continuation of the Company's consistent and predictable organic growth.
• Dave Doherty, Chief Financial Officer, commented, 'We are pleased to deliver these fourth quarter and full year results, which reflect our disciplined management approach, strong underlying business fundamentals and the benefits of our multi-year growth investments.'
• Dave Doherty also mentioned that the company enters 2025 with a liquidity position of over $770 million, enhancing their ability to fund accretive M&A without accessing capital markets.

Industry Context

Surgery Partners operates in the healthcare services industry, specifically focusing on short-stay surgical facilities. The company's growth strategy involves organic expansion through same-facility revenue increases, as well as strategic acquisitions and the development of de novo facilities. The industry is competitive and subject to regulatory changes and reimbursement pressures from government and private payors.

Comparison to Industry Standards

• It is difficult to provide a direct comparison to industry standards without specific competitor data.
• However, companies like AmSurg (now part of Envision Healthcare) and United Surgical Partners International (USPI) are major players in the ambulatory surgery center (ASC) market.
• Surgery Partners' same-facility revenue growth of 8.0% for the full year 2024 suggests a strong performance compared to the overall market, but a detailed benchmark would require analyzing the performance of these specific competitors.
• The company's focus on strategic acquisitions and de novo facilities is a common strategy in the industry to expand market presence and service offerings.

Stakeholder Impact

• Shareholders: The results indicate positive growth and potential for future value creation.
• Employees: The company's growth and expansion may lead to increased job opportunities.
• Patients: Surgery Partners aims to provide high-quality, cost-effective surgical solutions.
• Physicians: The company's success is tied to maintaining strong relationships with physician partners.
• Health Plans: Surgery Partners offers value to health plans through its outpatient delivery model.

Next Steps

• The company will continue to focus on organic growth, strategic acquisitions, and the development of de novo facilities.
• Surgery Partners will hold a conference call on March 3, 2025, to discuss the results.

Key Dates